Quick summary
Gonadorelin is a synthetic decapeptide identical to endogenous GnRH, FDA-approved and used clinically to stimulate LH and FSH release from the pituitary. It is widely used off-label in TRT protocols to maintain testicular function and preserve fertility during testosterone replacement.
Overview
Gonadorelin is a synthetic decapeptide identical in structure to endogenous gonadotropin-releasing hormone (GnRH), produced naturally by the hypothalamus. It is FDA-approved and used clinically to stimulate the pituitary gland, maintain testicular function in men on testosterone replacement therapy, treat hypogonadotropic hypogonadism, and support fertility. It is administered in pulsatile protocols to mimic natural hormonal signaling.
Mechanism of action
Gonadorelin binds to GnRH receptors on pituitary gonadotrope cells, triggering the synthesis and pulsatile release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates Leydig cells in the testes to produce testosterone, while FSH supports Sertoli cells and spermatogenesis. The pulsatile pattern is critical — continuous administration causes receptor downregulation and desensitization, paradoxically suppressing gonadotropin output (the basis of GnRH agonist-based androgen deprivation therapy). When dosed correctly in pulses every 60–120 minutes, gonadorelin preserves the hypothalamic-pituitary-gonadal (HPG) axis feedback loop, maintaining intratesticular testosterone and sperm production even in men receiving exogenous testosterone.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| TRT testicular maintenance | subcutaneous | 100–100 mcg | 2-3x per week | Inject subcutaneously. Goal is LH/FSH stimulation to preserve testicular size and intratesticular testosterone on TRT. |
| Hypogonadotropic hypogonadism / fertility | subcutaneous | 5–20 mcg | Pulsatile, every 90-120 minutes via infusion pump | Delivered via portable infusion pump. Pulsatile dosing is essential — continuous exposure suppresses rather than stimulates. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Gonadorelin has an extensive clinical evidence base as an FDA-approved diagnostic and therapeutic agent. In TRT protocols, it is used off-label to prevent testicular atrophy by preserving LH and FSH signaling. Studies show pulsatile GnRH delivery restores fertility in men with hypogonadotropic hypogonadism. Research confirms that 100 mcg subcutaneous doses two to three times weekly can partially preserve testicular volume and intratesticular testosterone compared to TRT-only protocols, though evidence for full fertility preservation on concurrent TRT is mixed.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Gonadorelin for synergistic effects.
Legal status
FDA-approved for diagnostic evaluation of pituitary function and treatment of primary hypothalamic amenorrhea and hypogonadotropic hypogonadism. Used off-label in TRT protocols via compounding pharmacies. Lutrepulse (pump-delivered gonadorelin) was FDA-approved for ovulation induction. Available through licensed compounding pharmacies in injectable form.
Sourcing & access
Prescription required
Gonadorelin is an FDA-approved prescription medication available through licensed healthcare providers, telehealth platforms, and 503A/503B compounding pharmacies.
Frequently asked questions
Gonadorelin is a synthetic decapeptide identical in structure to endogenous gonadotropin-releasing hormone (GnRH). It is FDA-approved for diagnostic evaluation of pituitary function and treatment of hypogonadotropic hypogonadism, and is widely used off-label in TRT protocols.
Gonadorelin binds GnRH receptors on pituitary gonadotrope cells, triggering LH and FSH release. LH stimulates testosterone production in Leydig cells, while FSH supports spermatogenesis. Pulsatile dosing is critical, as continuous exposure paradoxically suppresses gonadotropin output.
Side effects include injection site irritation, headache, nausea, flushing, and abdominal discomfort. The most important risk is receptor desensitization from continuous (non-pulsatile) dosing, which suppresses rather than stimulates hormone production.
Exogenous testosterone suppresses the HPG axis, causing testicular atrophy and infertility. Gonadorelin at 100 mcg subcutaneously 2-3 times weekly partially preserves LH/FSH signaling, maintaining testicular volume and intratesticular testosterone production.
Gonadorelin acts upstream at the pituitary to stimulate LH release naturally, while HCG directly mimics LH at the testicular level. Gonadorelin better preserves the full HPG axis feedback loop, though evidence for full fertility preservation on concurrent TRT is mixed.
Research references
- Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancerPubMed
- Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostatePubMed
- Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluationPubMed
- Development of GnRH antagonists for prostate cancer: new approaches to treatmentPubMed
- Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical TrialPubMed